Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neomycin vs Rifaximin + Neomycin in Methane-Positive IBS-C
NCT00945334Phase 2Completed
- Start
- Aug 2009
- Primary completion
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in irritable bowel syndrome (IBS) comparing Neomycin + Placebo with Neomycin + Rifaximin (2 arms). Primary endpoint: Severity of Constipation in Each Arm at Week 1 After Completion of Therapy. Started Aug 2009; status: completed.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)
Beyond the preview
Go deeper on NCT00945334.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00945334.